Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Agilent Technologies Lifts Outlook After Strong Quarter

📈 Agilent beat Q2 estimates with $1.83B revenue (10% reported growth) and $1.49 EPS, exceeding guidance by $0.07.

💰 Full-year FY26 outlook was raised to $7.39B-$7.49B revenue and $6.00-$6.10 EPS, signaling strong confidence in execution.

🔬 Applied Markets Group grew 11% core while Life Sciences & Diagnostics rose 9%, driven by semiconductor-related spectroscopy demand.

🛠️ Operating margins expanded to 26.4% due to strategic pricing adding 200 bps and the Ignite efficiency program.

🇨🇳 China revenue fell 9% in Q2, leaving H1 flat, with management expecting stimulus benefits to materialize next fiscal year.

🍔 Food testing segment outlook was cut to a low-single-digit decline due to funding delays in China and India.

🎓 Academia and government revenue dropped 5% as unfavorable grant timing continues to weigh on this vertical.

💵 Strong cash generation produced $277M operating cash flow against $76M capex, with $65M in share repurchases.

🚀 New product launches like the Altura Ultro Inert LC columns saw over 50% sequential growth in top biopharma accounts.

⚠️ Management warns of tougher year-over-year comparisons in H2 and potential input cost pressures from Middle East conflicts.

Bullish Signals
  • Agilent significantly upgraded its full-year revenue guidance to $7.39B-$7.49B, implying core growth of 4.5%-6.0%.
  • The company achieved a Non-GAAP operating margin of 26.4%, up 130 basis points year-over-year due to pricing power and cost controls.
  • Applied Markets Group delivered 11% core growth, with spectroscopy showing double-digit gains linked to the semiconductor cycle.
  • Agilent beat EPS guidance by $0.07, demonstrating solid operating leverage despite ongoing investments in growth initiatives.
  • The Ignite productivity program and tariff task force successfully offset new tariffs and reduced manufacturing overhead by over 50 basis points.
  • Instrument demand remains healthy with a book-to-bill ratio above 1.0 for the ninth consecutive quarter.
  • New product launches, specifically Altura Ultro Inert LC columns, achieved sequential growth above 50% in top biopharma accounts.
  • The company returned $65 million to shareholders via share repurchases while maintaining a conservative net leverage of 0.7 times.
Risk Factors
  • China revenue declined 9% in Q2, leaving the first half roughly flat due to Lunar New Year timing and delayed government funding.
  • The food testing segment outlook was cut from flat to a low-single-digit decline due to funding delays in China and India.
  • Academia and government revenue dropped 5% as unfavorable grant cycles and multi-year funding timing persist.
  • CrossLab Group growth slowed to just 2% core due to Lunar New Year effects and difficult comparisons against pre-tariff stocking.
  • Rising input costs linked to the Middle East conflict and strong memory chip demand are pressuring margins in the near term.
  • Management notes that full-year guidance does not factor in potential tariff refunds or benefits from the Biocare acquisition, creating a conservative tilt.
  • Executives flagged that year-over-year comparisons will stiffen in the second half of the fiscal year, making sustained growth rates harder to achieve.
Full Analysis
Agilent Technologies (A) reported a strong second quarter, beating revenue, margin, and EPS expectations. The company posted Q2 revenue of $1.83 billion, representing a 10% reported increase driven by core growth of 6.3% and a 3.7% currency tailwind. Non-GAAP operating margins expanded to 26.4%, up 130 basis points year-over-year, while EPS reached $1.49, beating prior guidance by $0.07. Management significantly upgraded its full-year fiscal 2026 outlook, raising the revenue range to $7.39 billion to $7.49 billion and increasing EPS guidance to $6.00 to $6.10. This positive revision reflects strong order books, pricing power, and successful cost controls via the Ignite productivity program, which offset macroeconomic headwinds and geopolitical tensions. Key growth drivers included double-digit gains in spectroscopy within Applied Markets and robust performance in Life Sciences & Diagnostics. However, near-term challenges persist due to a 9% decline in China revenue, delays in food testing funding, and softness in academia and government sectors. Despite these headwinds, the company maintains a solid balance sheet with healthy cash generation and a net leverage ratio of approximately 0.7 times.